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1. Lipids and CVD risk.  
 
Lipid abnormalities account for over 60% of the population attributable risk for myocardial infarction 
and are the most important single target for prevention, along with blood pressure lowering and 
smoking cessation. The low-density lipoprotein cholesterol (LDL-C) axis is an established therapeutic 
target in CVD.1 In contrast to genetic disorders that lead to higher or lower LDL-C, genetic mutations 
that affected high-density lipoprotein-cholesterol (HDL-C) did not translate into altered CVD risk.2 
Niacin and two cholesterol ester transferase protein (CETP) inhibitors that raise HDL-C failed to 
improve cardiovascular (CV) outcome on top of statins. Research on HDL mainly focused on the anti-
atherogenic functions of HDL. Although statistically high HDL-C is associated with reduced risk of 
CVD, some patients with very high HDL-C are actually at increased risk of CVD.3 Thus, not all HDL 
elevations are protective.  
 
While there is a well-known inverse correlation between plasma HDL and atherosclerosis since the 
initial observation by Barr, Russ and Eder in the early 1950s4, it is now apparent that HDL-C is not a 
good surrogate measure for therapeutics or functionality. A consensus is building that HDL function 
may be a better target than HDL-C. In 1974, Bates and Rothblat demonstrated that HDL can mediate 
sterol efflux from mouse macrophage cell lines.5 Cholesterol efflux capacity (CEC) can vary by a 
factor of two at a given concentration of HDL-C. Thus far, several studies have used CEC.6,7 In 
contrast to HDL-C, CEC is inversely correlated to CVD risk and low CEC is an independent risk factor 
for CVD. This metric of HDL function, however, involves cellular assays, and there is a need for better 
measurements than CEC that address the diverse functionality of HDL particles. Firstly, the same 
HDL can result in a range of different read-outs for CEC if incubated with different murine cell types. 
Secondly, a cellular assay is less suitable for routine clinical implementation. The assessment of 
lipoprotein composition is easier to incorporate into routine biomarker assays but must relate to 
lipoprotein function.  
 
Current laboratory measurements of plasma lipids principally involve total cholesterol HDL-C and 
triglycerides. LDL-C is not always measured for CVD risk assessment but calculated according to the 
Friedewald formula. Among apolipoproteins, the main focus has been on apoB-100 and apoA-1. In 
comparison, other apolipoproteins have received considerably less attention, with the exception of 
Lp(a) that has an incremental predictive effect for CVD risk.8, 9  
 
 
2. Lipidomics applied to epidemiological cohorts 
 
We have recently reported a lipidomic signature of CVD, in which select triglyceride species in whole 
plasma outperformed cholesterol esters.10 This was the first prospective, community-based study 
reporting a systematic analysis of the plasma lipidome in the context of CVD. Using mass 
spectrometry (MS), we detected 135 different lipid species attributable to 8 different lipid classes in 
plasma samples of the Bruneck Study. Samples from the UK Twin Registry were used for validation 
purposes. The study allowed four main conclusions:  
(i) There is a broad diversity of potential CV effects of lipid species within most lipid classes, 
and as a consequence, individual lipids outperform lipid summary measures with regard to CVD risk 
prediction;  
(ii) Lipid species of low carbon number and double-bond content show the strongest and most 
consistent positive associations with CVD; 
(iii) Molecular lipid profiling by MS results in a significant improvement in CVD risk 
discrimination and classification beyond the information provided by classic risk factors, including 
conventional lipid measures; and 
(iv) The stronger association of certain lipid species with CVD can, at least in part, be 
explained by a shift in the plasma fatty acid composition.  
The importance of individual lipid species in the context of CVD may have been underestimated by an 
unwarranted focus on lipid classes. Based on the traditional lipid measures of total triglycerides, total 
cholesterol, LDL-C and HDL-C, our understanding of the role of lipids in the pathophysiology of CVD 
is mainly confined to lipid classes rather than detailed molecular entities (i.e., the type of fatty acids 
that are conjugated to the glycerol backbone). Thus, different molecular lipid species exert different 
biological effects, and important information may be missed by sum measurements such as total 
triglycerides. In contrast to cholesterol, triglycerides were long thought to be merely a risk marker for 
CVD, in part due to their inverse correlation with HDL-C. Evidence from two recent Mendelian 
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randomisation studies11, 12 support a primary role of triglyceride-rich lipoproteins (TRL) for CVD. Loss-
of-function mutations in apoC-3 reduce triglyceride levels13 and result in a 40% reduction of CVD.11, 12 
It is thought that TRL remnants can penetrate the arterial intima, and that their cholesterol content is 
potentially more atherogenic than that of LDL.14 Importantly, TRL lipoproteins carry apoB-100. Current 
measurements for apoB do not discriminate between LDL and other apoB-100 carrying lipoprotein 
particles, including TRL. Thus, there is an unmet need for more comprehensive measurements that 
address the diverse functionality of apolipoprotein particles. Lipoprotein composition, which might be 
easier to develop into a routine biomarker, must relate to lipoprotein function. 
 
3. Proteomics applied to epidemiological cohorts 
 
In addition to lipidomic profiling, we have also used a multiple reaction monitoring–mass spectrometry 
(MRM-MS) platform for apolipoprotein profiling. MRM-MS was selected by Nature Methods as 
technology of the year in 2012. MRM-MS allows measurements of an unprecedented number of 
apolipoproteins with high specificity and without the constraints of antibodies. Due to its selectivity, the 
technology is the “gold standard” in the quantitation of small molecules. MRM-MS is already used in 
clinical applications such as screens for inborn errors of metabolism, drug abuse, toxicology, and 
monitoring plasma concentrations of therapeutic drugs. More recently, its amenability for high 
throughput analysis of plasma proteins in epidemiological research has become apparent. Using 
MRM-MS, we simultaneously measured 13 apolipoproteins (apoA-1, apoA-2, apoB-100, apoA-4, 
apoC-1, apoC-2, apoC-3, apoD, apoE, apoH, apoJ, apoL-1 and apoM) in the Bruneck study, an 
ongoing prospective community-based survey that ranks among the most successful epidemiological 
studies on CVD.15 The Bruneck Study offers 25 years of follow-up with detailed clinical assessments 
and samples collected every 5 years (age range of participants at baseline: 40-79 years, N=1,000). 
Lipid variables were clustered using agglomerative hierarchical clustering on the basis of complete 
linkage, defining the distance between 2 variables as 1 minus their correlation. Within the dependency 
structure of plasma apolipoproteins, multiple nested clusters emerged. Clusters are groups of 
variables with high intercorrelations and similar correlations with the other variables. One of the most 
prominent clusters included apoB-100, non-HDL cholesterol, apoE, triglycerides, apoC-2, and apoC-
3, thus reflecting apoB-containing lipoproteins. This cluster contained two sub clusters with apoC-2, 
apoC-3, triglycerides (representing VLDL) and apoB-100, non-HDL-C (representing LDL). Other 
notable clusters included apoA-2, apoM, and apoC-1, or HDL cholesterol and apoA-1. After 
adjustment for age, sex and statin therapy, the strongest association with incident CVD was not 
observed for apoB-100, but for three other apoIipoproteins: apoC-3 (hazard ratio per 1 standard 
deviation higher level, 95% confidence interval: 1.37, 1.16 to 1.62), apoC-2 (1.39, 1.17 to 1.66), and 
apoE (1.30, 1.12 to 1.51; all P<0.001). The associations for apoC-3, apoC-2, and apoE were 
attenuated but remained significant under adjustment for CVD risk factors, including the conventional 
lipid measures such as total and HDL cholesterol as well as systolic blood pressure, type 2 diabetes 
and smoking. Our finding that not apoB-100 but C apolipoproteins and apoE had the most significant 
associations with CVD underscores the importance of TRLs for the pathogenesis of CVD. Similar 
results have since been reported from a larger prospective cohort with 832 coronary artery disease 
cases and 1879 controls: when investigating apoC-3 levels using antibody based methods in 2711 
participants, Capelleveen and colleagues found apoC-3 levels to be higher in cases compared with 
controls. The  association of apoC-3 levels with incident CAD risk was indpenedent of traditional CVD 
risk factors. ApoC-3 was strongly associated with higher VLDL as well as IDL particle numbers, larger 
VLDL mean particle size, a shift towards small dense LDL particle size, and inflammation.16  
 
 
4. Future outlook 
 
Currently, apolipoproteins are not directly measured in patients with CVD. The function and 
metabolism of lipoproteins is governed by their apolipoproteins, yet there was no attempt to quantify a 
comprehensive panel of plasma apolipoproteins by MRM-MS and assess their comparative 
association with future CVD in the general community. Previous studies have related plasma levels of 
apolipoproteins to CVD with the use of available immunoassays. Historically the focus was mostly 
restricted to apoB-100 and apoA-1, even though other apolipoproteins, in particular apoC-3, have 
been independently linked to CVD. We capitalized on our proteomics expertise by applying MRM-MS 
to measure apolipoproteins in a community-based study. Among a broad panel of plasma 
apolipoproteins quantified by MRM-MS, VLDL-associated apolipoproteins were most significantly 
related to CVD. There is an unmet need for comprehensive apolipoprotein and lipidomics 
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measurements. With the advent of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
and novel RNA therapeutics, there is a renewed interest in lipid metabolism and CVD. For example, 
we determined the effects of apoC-3 inhibition by Volanesorsen, a second-generation antisense drug 
targeting apoC-3, using samples from 2 human intervention trials (IONIS1 and IONIS2).15 As 
expected, MRM-MS showed reduced plasma levels of apoC-3 but also revealed reductions in apoC-2 
and apoE. Along with lower triacylglycerols, lower diacylglycerol levels were observed. Thus, more 
comprehensive apolipoprotein measurements are needed not only in epidemiological cohorts to 
obtain a better understanding of the associations of apolipoproteins with CVD risk, but also in clinical 
trials for improved patient selection for evaluating treatment efficacy and safety. 
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